203 related articles for article (PubMed ID: 22430087)
1. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
4. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
5. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
Bradwell A; Harding S; Fourrier N; Mathiot C; Attal M; Moreau P; Harousseau JL; Avet-Loiseau H
Leukemia; 2013 Jan; 27(1):202-7. PubMed ID: 22699454
[TBL] [Abstract][Full Text] [Related]
7. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
8. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
[TBL] [Abstract][Full Text] [Related]
9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
10. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
[TBL] [Abstract][Full Text] [Related]
11. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
14. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) - Benefit for Stratification of Multiple Myeloma?].
Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
19. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
20. Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma.
Butch AW; Badros A; Desikan KR; Munshi NC
Bone Marrow Transplant; 2001 Mar; 27(6):663-6. PubMed ID: 11319600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
